TLOG (TetraLogic Pharmaceuticals) EV-to-EBIT: 0.00 (As of Jul. 07, 2026)


What is TetraLogic Pharmaceuticals EV-to-EBIT?

TetraLogic Pharmaceuticals TLOG EV-to-EBIT is 0.00 as of Jul. 07, 2026.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, TetraLogic Pharmaceuticals's Enterprise Value is $0.00 Mil. TetraLogic Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2016 was $-36.24 Mil. Therefore, TetraLogic Pharmaceuticals's EV-to-EBIT for today is 0.00.

The historical rank and industry rank for TetraLogic Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

TLOG's EV-to-EBIT is not ranked *
in the Biotechnology industry.
Industry Median: 14.69
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. TetraLogic Pharmaceuticals's Enterprise Value for the quarter that ended in Sep. 2016 was $28.83 Mil. TetraLogic Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2016 was $-36.24 Mil. TetraLogic Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2016 was -125.72%.

TetraLogic Pharmaceuticals  (OTCPK:TLOG) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

TetraLogic Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2016 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2016 ) =EBIT / Enterprise Value (Q: Sep. 2016 )
=-36.24/28.8251175
=-125.72 %

TetraLogic Pharmaceuticals's Enterprise Value for the quarter that ended in Sep. 2016 was $28.83 Mil.
TetraLogic Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-36.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TetraLogic Pharmaceuticals EV-to-EBIT Related Terms

TetraLogic Pharmaceuticals EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for TetraLogic Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TetraLogic Pharmaceuticals EV-to-EBIT Chart

TetraLogic Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15
EV-to-EBIT
0.00 0.00 -9.09 -2.47 -1.17

TetraLogic Pharmaceuticals Quarterly Data
Dec11 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.10 -1.17 -0.46 -0.80 -0.80

TLOG vs ARGSQ, GTHR, SOAN: EV-to-EBIT Comparison

For the Biotechnology subindustry, TetraLogic Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TetraLogic Pharmaceuticals EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TetraLogic Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where TetraLogic Pharmaceuticals's EV-to-EBIT falls into.


TetraLogic Pharmaceuticals EV-to-EBIT Calculation

TetraLogic Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.000/-36.24
=0.00

TetraLogic Pharmaceuticals's current Enterprise Value is $0.00 Mil.
TetraLogic Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-36.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-EBIT →
What does a EV-to-EBIT of 0.00 mean?
TetraLogic Pharmaceuticals (TLOG) has a EV-to-EBIT of 0.00 as of Jul. 07, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on TetraLogic Pharmaceuticals and its competitors.
Is TetraLogic Pharmaceuticals' EV-to-EBIT too high?
TetraLogic Pharmaceuticals' current EV-to-EBIT is 0.00.
How does TetraLogic Pharmaceuticals' EV-to-EBIT compare to ARGSQ and GTHR?
TetraLogic Pharmaceuticals' EV-to-EBIT of 0.00 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBIT is 14.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.69, based on 365 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on TetraLogic Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TetraLogic Pharmaceuticals's current EV-to-EBIT is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TetraLogic Pharmaceuticals stock overvalued right now?
TetraLogic Pharmaceuticals (TLOG) has a current EV-to-EBIT of 0.00. The current EV-to-EBIT is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For TetraLogic Pharmaceuticals (TLOG), the current EV-to-EBIT is 0.00 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TetraLogic Pharmaceuticals Business Description

Address 343 Phoenixville Pike, Malvern, PA, USA, 19355
TetraLogic Pharmaceuticals Corp is a biopharmaceutical company. The company is engaged in developing novel small molecule therapeutics in oncology.